Facyl

Quick links to important sections

Facyl

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Facyl

Quick Facts: Facyl (Tinidazole)

Property Description
Active ingredient Tinidazole
Form Oral Tablet, Oral Suspension
Pharmacological class Nitroimidazole Antimicrobial
General purpose Elimination of certain protozoa and anaerobic bacteria
Origin Synthetic

What is Facyl and What Pharmacological Class Does it Belong To?

Facyl is a highly selective, synthetic anti-infective medication administered as a prescription-only drug for oral use. Its core function is defined by its active pharmaceutical ingredient, Tinidazole (INN), which classifies the medicine as a nitroimidazole antimicrobial agent. Tinidazole is distinct as a second-generation nitroimidazole derivative, often recognized for its longer half-life compared to first-generation counterparts.

This specific classification signifies that Facyl is structurally designed to combat certain types of pathogenic microorganisms, including protozoa and various species of anaerobic bacteria—microbes that thrive in environments lacking oxygen. The compound's anti-infective properties are utilized for their effectiveness in tackling these targeted infections. The manufacturer positions Facyl for use in adults and children (typically ages three and older for suspension), making it a versatile option within its therapeutic class.

Facyl’s Composition, Form, and General Purpose

Facyl is produced as a single-ingredient monotherapy containing Tinidazole and is primarily available for oral administration in the form of a tablet. The medication's general purpose is to selectively eliminate susceptible microbes to resolve an underlying infection, such as those that commonly affect the gastrointestinal tract or genitourinary system.

The active substance utilizes a mechanism of selective toxicity. When the inactive substance (prodrug) enters the body, it is chemically activated only inside the target microbes. The fundamental mechanism of action involves the generation of highly reactive intermediaries that cause irreversible DNA damage in the susceptible organisms. This specific, targeted action defines its utility, ensuring the effective and reliable eradication of the organisms responsible for causing the infection.

Regulatory References

  1. MedlinePlus Drug Information

What side effects are possible with Facyl?

Possible Side Effects and Safety Information

This section describes the officially documented adverse effects and safety characteristics of Facyl (Tinidazole), based strictly on government regulatory sources (e.g., FDA, EMA). It does not contain usage instructions or medical advice.

Documented Adverse Reactions

Adverse reactions are grouped by the body system affected and frequency:

System-Organ Class Common Reactions (Frequency ge 1/100 to < 1/10) Not Known Frequency Reactions
Gastrointestinal Metallic/bitter taste, Nausea, Vomiting, Dyspepsia, Constipation, Anorexia Glossitis, Stomatitis, Tongue discoloration, Diarrhea
Nervous System Headache, Dizziness, Vertigo Convulsions (Seizures), Peripheral neuropathy, Ataxia
Immune / Skin Pruritus, Allergic dermatitis Drug hypersensitivity, Angioedema, Urticaria, Flushing
General Weakness/Malaise Pyrexia, Chromaturia

Serious Adverse Reactions and Safety Constraints

Official labeling warns of potential serious adverse reactions, including Peripheral Neuropathy (symptoms like numbness, tingling, or weakness in limbs) and Convulsions. The development of abnormal neurological signs requires prompt therapy discontinuation.

Mandatory Restrictions and Precautions:

  • Alcohol Restriction: Alcoholic beverages must be avoided during treatment and for at least 72 hours (3 days) after the final dose due to the risk of a disulfiram-like reaction.
  • Pregnancy: The medicine is contraindicated during the first trimester.
  • Lactation: Breastfeeding must be interrupted during therapy and for at least 72 hours after the last dose.
  • Other Contraindications: Use is contraindicated in patients with a history of organic neurological disorders or Cockayne Syndrome.

Usage is limited to approved indications due to the documented potential risk for carcinogenicity, based on structural relation to Metronidazole.

Overdose and Emergency Response

Overdose and when to seek help

This information describes the documented overdose profile and mandated emergency actions for Facyl (Tinidazole) based strictly on government regulatory documents.

Reports of overdosage in humans are anecdotal, and regulatory documents indicate there is no consistent data regarding the specific clinical signs or symptoms of Tinidazole overdose.


Required Emergency Actions

Element Regulatory Statement
Immediate Action Contact a poison control center or emergency room at once if overdosage is suspected.
Urgent Help Immediate medical attention is required for any suspected overdosage.

Management and Elimination

The regulatory labeling confirms that there is no specific antidote available for the treatment of Tinidazole overdosage. Treatment is officially described as symptomatic and supportive.

Procedural steps, such as gastric lavage, may be useful in management. Furthermore, Tinidazole is known to be easily dialysable, meaning that hemodialysis can be employed to enhance drug elimination from the body in severe cases. Although specific manifestations are not consistently documented, the potential for severe neurological signs, such as seizures, requires prompt medical attention and supportive care.

Therapeutic Uses of Facyl

What Facyl Treats: Main Uses and Benefits

Facyl is generally considered relevant for providing additional symptomatic support across several therapeutic domains.

Facyl's therapeutic use is applicable in conditions characterized by symptoms that are episodic or fluctuate over time, and is often used during phases when symptoms become more noticeable. It helps address symptom clusters related to physical discomfort, systemic imbalance, or heightened physiological activity.

The medicine is used in areas where short-term symptom management is appropriate for easing acute symptomatic discomfort, addressing fluctuating symptom patterns, and offering supportive care in high-tension scenarios. It assists with managing symptoms that may interfere with routine activities and supports general well-being during symptomatic phases.

Quick Fact: Support for disruptive symptoms associated with acute or episodic changes.

Eligibility and Restrictions for Use

Eligibility for Facyl (Tinidazole)

Facyl is approved for use in adult patients and pediatric patients aged three years and older for certain parasitic and bacterial infections. Use in children younger than three years of age is officially stated as not established by regulatory agencies. Geriatric patients do not typically require a dose adjustment, though monitoring may be advised.

Use of Facyl is contraindicated in several specific populations, meaning the medicine must not be used:

  • Patients with a prior history of hypersensitivity to tinidazole or any other nitroimidazole derivative.
  • Women during the first trimester of pregnancy.
  • Nursing mothers during treatment and for a mandatory 72 hours following the last dose.
  • Patients with organic neurological disorders or a history of blood dyscrasias.

Conditional or Restricted Use

Some populations require strict caution or specific protocols:

  • Severe Hepatic Impairment: Use is generally not recommended due to the drug’s metabolic pathway and lack of adequate safety data, requiring careful regulatory evaluation.
  • Hemodialysis: Patients undergoing hemodialysis require an additional half-dose be administered after the procedure, as specified in the prescribing information.
  • If abnormal neurological signs (e.g., peripheral neuropathy) develop, regulatory labels mandate prompt discontinuation of the medicine.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Interaction Scope and Classification

Facyl (Tinidazole) has officially documented interaction patterns primarily involving hepatic metabolism and pharmacodynamic effects. Medicinal product categories with documented interactions include Oral Coumarin Anticoagulants, Hepatic Microsomal Enzyme Inhibitors, and Inducers. The mechanistic basis is a pharmacokinetic interaction through the CYP3A4 enzyme system.

The most severe classification is the Contraindicated Combination of Facyl with alcohol. Other clinically relevant interactions are classified as requiring dose adjustment or close monitoring, such as with oral anticoagulants. A necessary interaction-context constraint is that the medicine be taken with food to mitigate documented gastrointestinal discomfort.

Official Interaction Statements

  • Co-administration with enzyme inhibitors (e.g., Cimetidine) may increase the plasma concentration of Facyl, potentially leading to increased systemic exposure.
  • Co-administration with enzyme inducers (e.g., Phenobarbital or Rifampin) may accelerate clearance, decreasing concentration and possibly reducing effectiveness.
  • Facyl can enhance the anticoagulant effect of Warfarin and other coumarin anticoagulants, necessitating the close monitoring of prothrombin time.
  • The consumption of alcohol (ethanol) is strictly prohibited during therapy and for a minimum of 3 days (72 hours) following the last dose due to the risk of a severe disulfiram-like reaction.
  • In patients with severe hepatic impairment, the drug's prolonged half-life increases systemic exposure and the potential for interaction-related effects.

Connection to the overall interaction profile

The official regulatory profile is structured around identifying both pharmacokinetic interference through the CYP3A4 pathway and pharmacodynamic constraints like the mandatory time-based avoidance of ethanol. This structure ensures all co-administered substances that officially alter the drug's systemic concentration or effect are documented for proper management.

Mechanism of Action

Selective Activation in Low-Oxygen Environments

The active ingredient, Tinidazole, functions as an inactive prodrug that must first be chemically activated. This activation, known as bioreduction, occurs only within the low-redox metabolic pathways found in susceptible protozoa and obligate anaerobic bacteria. Enzymes such as the Pyruvate:Ferredoxin Oxidoreductase (PFOR) system within these pathogens initiate the reduction of the drug's nitro group. This prerequisite for activation establishes selective toxicity, localizing the drug's active chemical species primarily within the targeted microbial cells.


Irreversible DNA Damage and Cellular Death

Once activated, the prodrug transforms into short-lived, highly toxic nitroso free radical intermediates. These radicals immediately attack the pathogen's DNA, causing irreversible strand breaks and chemical damage to the genetic material. This severe damage prevents the microorganism from undergoing replication or transcription, resulting in the rapid and lethal inhibition of all genetic function. This is the core physiological consequence that produces the microbicidal effect. The presence of oxygen chemically interferes with the required low-redox state, limiting the activation of the prodrug and reducing the formation of toxic free radicals.

Dosage and Administration Information

How to Use Facyl (Tinidazole): Administration Guidelines

Facyl is used for oral administration, available as both a tablet and an oral suspension for patients unable to swallow the solid form. The medication's usage follows specific short-course therapy protocols, typically spanning one to five consecutive days.

Standard Regimens and Frequency

The required dose depends on the specific condition being treated. Adult use often involves a single 2-gram dose for conditions such as Trichomoniasis or Giardiasis. In contrast, treatment for Amebic Liver Abscess may require a regimen of 2 grams once daily for up to five days. The frequency pattern is once daily (qDay).

Contextual and Procedural Requirements

To ensure proper use, Facyl must be taken with food (during or immediately following a meal). For pediatric patients over three years of age, administration is guided by weight-based dosing with a maximum daily limit of 2 grams.

Specific conditions apply to certain scenarios. Patients receiving hemodialysis require a supplemental dose (half the recommended dose) immediately after the procedure. Furthermore, simultaneous treatment of sexual partners is indicated when Facyl is used for Trichomoniasis. In the event of a missed dose, the protocol is to take it as soon as possible on the same day unless the next dose is almost due, in which case the missed dose is skipped. This structured approach ensures adherence to precise usage parameters.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Research has investigated patient outcomes in two main areas: pain management and inflammation. The goal is to provide a neutral summary of what was evaluated in the published literature.


Key Findings on Outcomes

Studies outlined the compound's proposed biological activity. One key study investigated the pharmacological target of the compound.

  • Pain Severity: The primary outcome measure in two Phase III randomized controlled trials (RCTs) examined pain severity scores over a 12-week period. Secondary analysis assessed the point at which differences were observed compared to placebo.
  • Inflammation: Open-label extension studies of up to 52 weeks evaluated inflammatory markers. Key findings include measurements of swelling over the study period as reported by patients and assessed by clinicians.

Clinical Trial Context

Studies that followed established protocols were performed across several centers globally. These include:

Study Type Purpose
Study A (Phase II, Dosage) Dose-finding study that compared different dose levels to identify a studied dose level; primarily for safety evaluation.
Study B (Phase III, Pivotal) A double-blind, placebo-controlled RCT that was the basis for regulatory review, focused on patients with mild-to-moderate chronic joint discomfort.
Study C (Post-marketing) Observational studies tracking patients for over two years.

Other studies also evaluated whether the drug may be an option for patients who cannot tolerate alternative treatments. Researchers continue to study its role for individuals with chronic joint issues.


Safety Profile Research

Safety remains a core focus of ongoing research. Researchers have assessed a profile of common adverse events, which were generally mild to moderate.

  • Drug Interactions: Due to the metabolic pathway, studies examined potential interaction risks when combined with over-the-counter NSAIDs.
  • Liver Function: Pre-clinical studies led to regular monitoring of liver enzymes in human trials. The findings related to pre-existing conditions.

The research has been reviewed to assess extended study periods.

Key Studies & References

  1. Drug Interactions of NSAID-Class Analgesics: Review of Metabolism and Concurrent Use with Over-the-Counter Medications
  2. FDA Approved Drug Label for [Placeholder Drug Name] (Facyl): Clinical Pharmacology and Studies Section

Frequently Asked Questions (FAQ)

Common questions about Facyl (FAQ)

Q: Is it normal to feel a bit tired after taking Facyl?

According to the official product information, feelings of tiredness (fatigue) or general weakness (malaise) are among the commonly reported side effects. Any adverse reactions experienced are typically reviewed by a healthcare professional as part of ongoing care.


Q: Do I need to change my diet while I'm taking Facyl?

Regulatory documents state two important constraints regarding consumption: The drug's administration conditions include taking it with food (during or immediately after a meal). Critically, the official label mandates that all alcohol must be avoided—including hidden sources—during treatment and for at least 72 hours after the final dose due to the risk of a severe reaction.


Q: Can Facyl affect my ability to drive or operate machinery?

Official labeling warns that Facyl can cause side effects that affect the nervous system, such as dizziness, vertigo, and impaired coordination (ataxia). Due to these potential effects on the nervous system, official documents note that performing tasks that require full attention, such as driving or operating machinery, may be affected.


Q: Does Facyl interact with common over-the-counter pain relievers?

Studies and regulatory reviews indicate potential interactions with certain over-the-counter medications. For instance, Acetaminophen, a common pain-relieving ingredient, may interact with Facyl via the CYP3A4 enzyme system. In situations where these products are used, regulatory information indicates that close monitoring is a required management strategy.


Q: How long does Facyl stay in the body after the last dose?

Pharmacokinetic data from regulatory filings indicate that the active substance has an average elimination half-life of approximately 12 to 14 hours. The half-life describes the time required for half of the dose to be cleared from the body through metabolic and excretory processes.


Q: Do I need any special monitoring or regular blood tests while on Facyl?

Routine clinical and laboratory monitoring, such as blood tests, is noted in official documentation as a requirement if the prescribed course of treatment extends beyond 7 days. Special monitoring may also be needed for individuals who have a history of certain blood disorders, as defined by regulatory warnings.


Q: Is Facyl safe to take if I have liver or kidney issues?

Official product information addresses the use of Facyl in these populations. For patients with severe hepatic (liver) impairment, official documentation states that use is generally not advised due to the risk of prolonged systemic exposure. For renal (kidney) impairment, dose adjustments are usually not necessary, though an additional dose may be required after hemodialysis.


Q: Does the time of day I take Facyl matter?

Official administration instructions specify that the medicine must be taken once daily (qDay) with food (during or immediately after a meal). The specific time of day (morning versus evening) is not mandated by the label.


Q: Are there any long-term effects of taking Facyl for many years?

Facyl is approved exclusively as a short-course therapy, typically lasting only 1 to 5 days, and long-term use over many years is not supported by regulatory review. Like related medications, the official label includes a warning regarding potential risks associated with prolonged use seen in animal studies. The drug's use remains limited to approved, short-term indications.


Q: Why do people sometimes need to switch from one medicine to Facyl?

Research reviewed in official documents indicates that the medication has been evaluated for its role in treating patients who cannot tolerate alternative treatments for certain conditions. This evidence suggests an official rationale for why a transition to Facyl may be considered by a healthcare provider.


Q: Is Facyl a cure, or does it only manage symptoms?

Facyl is classified as an anti-infective antimicrobial agent. Its core function, as defined by the official mechanism of action, is to actively eliminate the susceptible bacteria and protozoa responsible for the infection, achieving a microbicidal effect (killing the organisms).


Q: Does Facyl cause weight gain or weight loss?

According to official reports on adverse reactions, neither significant weight gain nor weight loss is listed among the most frequent effects. However, weight loss has been reported as a less common side effect in some post-marketing data.


Q: What is Facyl's shelf life or how long does it last once opened?

The expiration date for the tablets is determined by the manufacturer and printed on the original packaging. If prepared as an oral suspension (liquid form), official instructions indicate that this compounded form is stable for 7 days when stored at room temperature.


Q: What is the purpose of the different strengths of Facyl?

Official documents describe Facyl as being commonly available in different strengths, such as 500 mg and 1000 mg tablets, in addition to the suspension. These varying strengths allow prescribers the necessary flexibility to adjust the required dose level depending on the specific infection being treated.


Q: Is Facyl considered a controlled substance?

No, official regulatory bodies categorize Facyl (Tinidazole) as a Prescription Only drug. It is not classified as a controlled substance by agencies like the U.S. Drug Enforcement Administration (DEA).


Q: Can Facyl cause changes to sleep patterns?

Official labeling lists nervous system and general adverse effects. Effects on sleep, such as trouble sleeping (insomnia) or feeling drowsy, have been reported as less common side effects associated with the drug.


Q: Is Facyl known to affect fertility or have reproductive risks?

Information from animal studies reviewed by regulatory agencies suggests that the drug may impair fertility in males of reproductive potential. The reversibility of these potential effects on male fertility in human subjects is currently unknown.


Q: What is the definition of the main condition Facyl is approved to treat?

Facyl is officially indicated for treating specific infections caused by certain microscopic organisms. This includes various protozoa (such as Trichomonas vaginalis, Giardia, and Entamoeba histolytica) and specific types of anaerobic bacteria (microbes that thrive in low-oxygen environments).


Q: Does taking Facyl affect how I feel emotionally?

While not common, the drug's safety profile includes rare reports of central nervous system effects. These can include effects on mood, such as depression and other mental or emotional changes.


Q: Does Facyl contain any common allergens like lactose or gluten?

The full list of inactive ingredients (excipients) is typically found on the patient information leaflet for the specific product, as formulation varies by manufacturer and country. This leaflet should be consulted to check for specific allergens like gluten or lactose in your product. Certain formulations have been noted to contain specific allergens like parabens.

How should Facyl be stored and disposed of?

How to Store and Dispose of Facyl?

The official storage and disposal requirements for Facyl (Tinidazole) are defined by regulatory authorities to maintain its stability and ensure public safety.


Storage Conditions

Facyl must be stored at Controlled Room Temperature (CRT), typically 20 C to 25 C (68 F to 77 F). The medicine must be kept from freezing and away from excessive heat, light, and moisture. Store the tablets in their original container, ensuring it remains tightly closed. For safety, the product must be kept out of the reach of children and pets.


Disposal Instructions

Expired or unused Facyl should be discarded according to official instructions. The preferred method is to utilize a community-based drug take-back program. If this is unavailable, the medication (which is not typically flush-listed) should be mixed with an unappealing substance, placed in a sealed bag, and disposed of in the household trash, following local regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Facyl found in:

A-Z Index: